2025
Type 2 immunity to the rescue: enhancing antitumor immunity for skin cancer prevention
Vesely M, Christensen S. Type 2 immunity to the rescue: enhancing antitumor immunity for skin cancer prevention. Journal Of Clinical Investigation 2025, 135: e188018. PMID: 39744952, PMCID: PMC11684797, DOI: 10.1172/jci188018.Peer-Reviewed Original ResearchMeSH KeywordsAnimalsCalcitriolCarcinoma, Squamous CellCytokinesFluorouracilHumansInterleukinsKeratinocytesKeratosis, ActinicMiceSkin NeoplasmsTh2 CellsThymic Stromal LymphopoietinConceptsCutaneous squamous cell carcinomaThymic stromal lymphopoietinType 2 immunityActinic keratosisAK lesionsTh2 cellsPrevent cutaneous squamous cell carcinomaRecruitment of Th2 cellsCSCC preventionSquamous cell carcinomaMouse model of skin carcinogenesisModel of skin carcinogenesisDamage-associated molecular patternsKeratinocyte cell deathAntitumor immunityTopical calcipotriolSkin cancer preventionCell carcinomaPaired biopsiesPrecursor lesionsSkin carcinogenesisUnaffected skinMouse modelCancer preventionPremalignant keratinocytes
2024
Achieving Adherence With NCCN Guidelines for Nonmelanoma Skin Cancer Regarding Peripheral and Deep En Face Margin Assessment (PDEMA).
Xu Y, Lim Y, Bordeaux J, Aasi S, Alam M, Chen P, Contreras C, DiMaio D, Donigan J, Farma J, Grekin R, Mark L, Nehal K, Nghiem P, Olino K, Patel T, Scott J, Shaha A, Srivastava D, Schmults C. Achieving Adherence With NCCN Guidelines for Nonmelanoma Skin Cancer Regarding Peripheral and Deep En Face Margin Assessment (PDEMA). Journal Of The National Comprehensive Cancer Network 2024, 22 PMID: 39536442, DOI: 10.6004/jnccn.2024.7037.Peer-Reviewed Original ResearchMeSH KeywordsCarcinoma, Squamous CellGuideline AdherenceHumansMargins of ExcisionMohs SurgeryPractice Guidelines as TopicSkin NeoplasmsConceptsMargin assessmentCell carcinomaNCCN GuidelinesHigh-risk basal cell carcinomasCutaneous squamous cell carcinomaDeep margin assessmentMohs micrographic surgerySquamous cell carcinomaBasal cell carcinomaNonmelanoma skin cancerMicrographic surgeryDermatofibrosarcoma protuberansCure rateOptimal patient outcomesUninvolved tissueAccurate resectionSkin cancerPatient outcomesNCCNCarcinomaHistological visualizationMarginal surfacesTissueCCPDMAResectionStatins Inhibit Cutaneous Squamous Cell Carcinoma Cells
HACKETT A, COHEN A, RUTENBERG T, HODAK E, MOYAL L, ATZMONY L. Statins Inhibit Cutaneous Squamous Cell Carcinoma Cells. Acta Dermato Venereologica 2024, 104: 25097. PMID: 39185545, PMCID: PMC11367778, DOI: 10.2340/actadv.v104.25097.Peer-Reviewed Original ResearchExpression and prognostic value of cell‐cycle‐associated genes in lung squamous cell carcinoma
Xu X, Jin K, Xu X, Yang Y, Zhou B. Expression and prognostic value of cell‐cycle‐associated genes in lung squamous cell carcinoma. The Journal Of Gene Medicine 2024, 26: e3735. PMID: 39171952, DOI: 10.1002/jgm.3735.Peer-Reviewed Original ResearchConceptsCell cycle-associated genesLung squamous carcinomaCell cycleMRNA expression dataGene expression profilesAssociated with positive prognosisCause of cancer-related deathExpression dataCancer Genome AtlasExpressed genesSquamous cell carcinomaLung squamous cell carcinomaTargeted therapy trialsGroup of patientsCancer-related deathsExpression of CDK4GenesExpression trendsExpression profilesMolecular studiesGenome AtlasSquamous carcinomaCell carcinomaPathological stagePrognostic valueNovel non‐invasive molecular signatures for oral cavity cancer, by whole transcriptome and small non‐coding RNA sequencing analyses: Predicted association with PI3K/AKT/mTOR pathway
Vageli D, Doukas P, Townsend J, Pickering C, Judson B. Novel non‐invasive molecular signatures for oral cavity cancer, by whole transcriptome and small non‐coding RNA sequencing analyses: Predicted association with PI3K/AKT/mTOR pathway. Cancer Medicine 2024, 13: e7309. PMID: 38819439, PMCID: PMC11141334, DOI: 10.1002/cam4.7309.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedBiomarkers, TumorCarcinoma, Squamous CellCase-Control StudiesFemaleGene Expression ProfilingGene Expression Regulation, NeoplasticHumansMaleMicroRNAsMiddle AgedMouth NeoplasmsPhosphatidylinositol 3-KinasesProto-Oncogene Proteins c-aktRNA, MessengerRNA, Small UntranslatedSalivaSequence Analysis, RNASignal TransductionTOR Serine-Threonine KinasesTranscriptomeConceptsOral squamous cell carcinomaPost-treatment monitoringHealthy controlsOral cavity cancer patientsOral cavity cancerIdentification of molecular biomarkersSquamous cell carcinomaPatients relative to HCSamples of salivaMonitoring of patientsCell carcinomaPost-treatment monitoring of patientsSmoking historySerum miRNAsCancer patientsEfficient clinical toolEffective preventive careTherapeutic approachesMRNA signatureRNA sequencing analysisClinical testingSerumPatientsMolecular biomarkersClinical toolImmune infiltration at the primary tumor is associated with clinical outcome of patients with extranodal extension of lymph node metastasis in oral cancer
Michikawa C, Gleber-Netto F, Pickering C, Rao X, Wang J, Sikora A, Myers J, Frederick M. Immune infiltration at the primary tumor is associated with clinical outcome of patients with extranodal extension of lymph node metastasis in oral cancer. Oral Oncology 2024, 153: 106729. PMID: 38663156, DOI: 10.1016/j.oraloncology.2024.106729.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedCarcinoma, Squamous CellExtranodal ExtensionFemaleHumansLymphatic MetastasisMaleMiddle AgedMouth NeoplasmsPrognosisConceptsOral cavity squamous cell carcinomaAssociated with clinical outcomesExtranodal extensionLymph node metastasisImmune infiltrationImmune infiltration statusOverall survivalPrimary tumorNode metastasisOral cancerInfiltration statusClinical outcomes of OSCC patientsExtension of lymph node metastasesAssociated with clinical outcomes of patientsAssociated with OS rateLocally advanced oral cancerClinical outcomes of patientsOutcome of OSCC patientsAssociated with poor overall survivalImmune infiltration of tumorsLow immune infiltrationNode negative tumorsAdvanced oral cancerHuman papillomavirus-negativeInfiltration of tumorsSurrogate endpoints in clinical trials of p16-positive squamous cell carcinoma of the oropharynx: an individual patient data meta-analysis
Gharzai L, Morris E, Suresh K, Nguyen-Tân P, Rosenthal D, Gillison M, Harari P, Garden A, Koyfman S, Caudell J, Jones C, Mitchell D, Krempl G, Ridge J, Gensheimer M, Bonner J, Filion E, Dunlap N, Stokes W, Le Q, Torres-Saavedra P, Mierzwa M, Schipper M. Surrogate endpoints in clinical trials of p16-positive squamous cell carcinoma of the oropharynx: an individual patient data meta-analysis. The Lancet Oncology 2024, 25: 366-375. PMID: 38423050, PMCID: PMC10962533, DOI: 10.1016/s1470-2045(24)00016-0.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentAdultBiomarkersCarcinoma, Squamous CellFemaleHumansMaleMiddle AgedMotivationOropharyngeal NeoplasmsConceptsLocoregional progression-free survivalProgression-free survivalIntermediate clinical endpointsMetastasis-free survivalOverall survivalClinical endpointsOropharyngeal cancerComposite endpointIncidence of human papillomavirus (HPV)-related cancersP16-positive squamous cell carcinomaHuman papillomavirus (HPV)-related cancersP16-positive oropharyngeal cancerCancer treated with chemotherapyIndividual patient data meta-analysisMedian follow-upPatient data meta-analysisSquamous-cell carcinomaSquamous cell carcinomaPatient levelClinical trial endpointsTreatment effectsData meta-analysisLocoregional progressionNational Cancer InstituteDistant metastasisMulti-omics analysis reveals immune features associated with immunotherapy benefit in squamous cell lung cancer patients from Phase III Lung-MAP S1400I trial
Parra E, Zhang J, Duose D, Gonzalez-Kozlova E, Redman M, Chen H, Manyam G, Kumar G, Zhang J, Song X, Lazcano R, Marques-Piubelli M, Laberiano-Fernandez C, Rojas F, Zhang B, Taing L, Jhaveri A, Geisberg J, Altreuter J, Michor F, Provencher J, Yu J, Cerami E, Moravec R, Kannan K, Luthra R, Alatrash G, Huang H, Xie H, Patel M, Nie K, Harris J, Argueta K, Lindsay J, Biswas R, Van Nostrand S, Kim-Schulze S, Gray J, Herbst R, Wistuba I, Gettinger S, Kelly K, Bazhenova L, Gnjatic S, Lee J, Zhang J, Haymaker C. Multi-omics analysis reveals immune features associated with immunotherapy benefit in squamous cell lung cancer patients from Phase III Lung-MAP S1400I trial. Clinical Cancer Research 2024, 30: 1655-1668. PMID: 38277235, PMCID: PMC11016892, DOI: 10.1158/1078-0432.ccr-23-0251.Peer-Reviewed Original ResearchConceptsChromosome copy-number variationsOverall survivalMultiplex immunofluorescenceMulti-omics analysisAssociated with superior progression-free survivalNCounter PanCancer Immune Profiling PanelSquamous cell lung cancer patientsSuperior progression-free survivalTreated with nivolumab monotherapyAssociated with worse overall survivalNon-small cell carcinomaAssociated with worse survivalCell lung cancer patientsCold immune microenvironmentProgression-free survivalImmune Profiling PanelRegulatory T cellsPhase III trialsResponse to ICIImmune cell infiltrationHigher immune scoresImmune cell densityLung cancer patientsWhole-exome sequencingImmune gene expression profiles
2023
Emerging Prognostic and Predictive Significance of Stress Keratin 17 in HPV-Associated and Non HPV-Associated Human Cancers: A Scoping Review
Lozar T, Wang W, Gavrielatou N, Christensen L, Lambert P, Harari P, Rimm D, Burtness B, Kuhar C, Carchman E. Emerging Prognostic and Predictive Significance of Stress Keratin 17 in HPV-Associated and Non HPV-Associated Human Cancers: A Scoping Review. Viruses 2023, 15: 2320. PMID: 38140561, PMCID: PMC10748233, DOI: 10.3390/v15122320.Peer-Reviewed Original ResearchConceptsSquamous cell carcinomaTriple-negative breast cancerCancer typesPredictive significancePrognostic factorsClinical outcomesPrognostic significanceCell carcinomaHuman cancersCervical squamous cell carcinomaNeck squamous cell carcinomaAvailable clinical evidenceCochrane Central RegisterInferior clinical outcomesPositive prognostic factorNegative predictive factorNegative prognostic factorWeb of ScienceCentral RegisterControlled TrialsCervical cancerClinical evidencePredictive factorsPancreatic cancerEligible studiesFAK drives resistance to therapy in HPV-negative head and neck cancer in a p53-dependent manner.
Pifer P, Yang L, Kumar M, Xie T, Frederick M, Hefner A, Beadle B, Molkentine D, Molkentine J, Dhawan A, Abdelhakiem M, Osman A, Leibowitz B, Myers J, Pickering C, Sandulache V, Heymach J, Skinner H. FAK drives resistance to therapy in HPV-negative head and neck cancer in a p53-dependent manner. Clinical Cancer Research 2023, 30: 187-197. PMID: 37819945, PMCID: PMC10767302, DOI: 10.1158/1078-0432.ccr-23-0964.Peer-Reviewed Original ResearchMeSH KeywordsCarcinoma, Squamous CellCell Line, TumorCisplatinHead and Neck NeoplasmsHumansPapillomavirus InfectionsSquamous Cell Carcinoma of Head and NeckTumor Suppressor Protein p53ConceptsHPV-negative headHPV-negative HNSCC tumorsWorse disease-free survivalNeck squamous cell carcinomaMutant TP53HPV-negative HNSCC cell linesBackbone of therapyDisease-free survivalPlatinum-based chemotherapySquamous cell carcinomaHPV-negative HNSCCHNSCC cell linesCell linesWild-type TP53Cisplatin-resistant cell linesCell carcinomaHNSCC cohortNeck cancerHNSCC tumorsVivo shRNA screenWorse outcomesClinical and oncological outcomes of pelvic exenteration surgery for anal squamous cell carcinoma
Quyn A, Murthy S, Gould L, Said H, Tiernan J, Sagar P, Antoniou A, Jenkins I, Burns E. Clinical and oncological outcomes of pelvic exenteration surgery for anal squamous cell carcinoma. Colorectal Disease 2023, 25: 2131-2138. PMID: 37753947, DOI: 10.1111/codi.16736.Peer-Reviewed Original ResearchMeSH KeywordsAnus NeoplasmsCarcinoma, Squamous CellHumansNeoplasm Recurrence, LocalPelvic ExenterationRectal NeoplasmsRetrospective StudiesTreatment OutcomeConceptsAnal squamous cell carcinomaSquamous cell carcinomaDisease-free survivalR0 resectionR1/R2 resectionPelvic exenterationOverall survivalRecurrent diseaseCell carcinomaTreated with pelvic exenterationComplete R0 resectionPelvic exenteration surgeryAnal cancer incidenceR0 resection rateMedian follow-upPoorer overall survivalR1/2 resectionR1 resectionR2 resectionExenteration surgeryOncological outcomesResection ratePrimary endpointRetrospective reviewTreatment modalitiesA Novel Saliva and Serum miRNA Panel as a Potential Useful Index for Oral Cancer and the Association of miR-21 with Smoking History: a Pilot Study.
Vageli D, Doukas P, Shah R, Boyi T, Liu C, Judson B. A Novel Saliva and Serum miRNA Panel as a Potential Useful Index for Oral Cancer and the Association of miR-21 with Smoking History: a Pilot Study. Cancer Prevention Research 2023, 16: 653-659. PMID: 37683274, DOI: 10.1158/1940-6207.capr-23-0219.Peer-Reviewed Original ResearchMeSH KeywordsBiomarkers, TumorCarcinoma, Squamous CellHead and Neck NeoplasmsHumansMicroRNAsMouth NeoplasmsPilot ProjectsSalivaSmokingSquamous Cell Carcinoma of Head and NeckConceptsOral squamous cell carcinomaSerum miR-21Oral cancerMiR-136MiR-21Smoking historyPilot studySerum miRNAsEarly-stage oral squamous cell carcinomaMiR-29bSquamous cell carcinomaEarly malignant lesionsEarly-stage tumorsSerum miRNA panelFurther validationUseful indexSmoking statusCell carcinomaHealthy controlsPoor survivalTobacco useHealthy volunteersLarge cohortMalignant lesionsSmokersExtra imaging beyond NCCN surveillance guidelines is cost effective for HPV− but not HPV+ oropharyngeal cancer
Shah R, Tyagi S, Liu C, Judson B. Extra imaging beyond NCCN surveillance guidelines is cost effective for HPV− but not HPV+ oropharyngeal cancer. Oral Oncology 2023, 146: 106564. PMID: 37672950, DOI: 10.1016/j.oraloncology.2023.106564.Peer-Reviewed Original ResearchMeSH KeywordsCarcinoma, Squamous CellCost-Benefit AnalysisDiagnostic ImagingHumansOropharyngeal NeoplasmsPapillomaviridaePapillomavirus InfectionsOutcomes of Treatment With Neoadjuvant Cemiplimab for Patients With Advanced, Resectable Cutaneous Squamous Cell Carcinoma of the Head and Neck
Ferrarotto R, Nagarajan P, Maronge J, Johnson J, Rosenthal D, Myers J, Gross N. Outcomes of Treatment With Neoadjuvant Cemiplimab for Patients With Advanced, Resectable Cutaneous Squamous Cell Carcinoma of the Head and Neck. JAMA Otolaryngology - Head & Neck Surgery 2023, 149: 847-849. PMID: 37535378, PMCID: PMC10401391, DOI: 10.1001/jamaoto.2023.1729.Peer-Reviewed Original ResearchMeSH KeywordsCarcinoma, Squamous CellHead and Neck NeoplasmsHumansNeoadjuvant TherapySkin NeoplasmsSquamous Cell Carcinoma of Head and NeckTreatment OutcomeBreast implant capsule-associated squamous cell carcinoma: A systematic review and individual patient data meta-analysis
Yeow M, Ching A, Guillon C, Alperovich M. Breast implant capsule-associated squamous cell carcinoma: A systematic review and individual patient data meta-analysis. Journal Of Plastic Reconstructive & Aesthetic Surgery 2023, 86: 24-32. PMID: 37666057, DOI: 10.1016/j.bjps.2023.08.002.Peer-Reviewed Original ResearchMeSH KeywordsBreastBreast ImplantationBreast ImplantsBreast NeoplasmsCarcinoma, Squamous CellFemaleHumansMiddle AgedConceptsIndividual patient dataSCC diagnosisPatient dataSystematic reviewJoanna Briggs Institute critical appraisal toolsDisease-free survivalMajority of patientsSquamous cell carcinomaRisk of biasRisk of malignancyCritical appraisal toolExtracapsular spreadMean followOverall survivalMedian ageMedian timeCell carcinomaBreast implantationImplant removalPatientsBreast augmentationUS FoodDrug AdministrationBreast implantsAppraisal toolNoncanonical HPV carcinogenesis drives radiosensitization of head and neck tumors
Schrank T, Kothari A, Weir W, Stepp W, Rehmani H, Liu X, Wang X, Sewell A, Li X, Tasoulas J, Kim S, Yarbrough G, Xie Y, Flamand Y, Marur S, Hayward M, Wu D, Burtness B, Anderson K, Baldwin A, Yarbrough W, Issaeva N. Noncanonical HPV carcinogenesis drives radiosensitization of head and neck tumors. Proceedings Of The National Academy Of Sciences Of The United States Of America 2023, 120: e2216532120. PMID: 37523561, PMCID: PMC10410762, DOI: 10.1073/pnas.2216532120.Peer-Reviewed Original ResearchConceptsNF-κB-related genesEstrogen receptor alpha expressionDeintensification of therapyTreatment-related morbidityTumor-infiltrating CD4Receptor alpha expressionHPV carcinogenesisRadiosensitization of headOncogenic subtypesPIK3CA alterationsHNSCC tumorsPatient outcomesNeck tumorsT cellsTreatment responseHNSCC cellsTherapeutic intensityAtypical featuresIndependent cohortAlpha expressionNF-κBActive tumorTNF receptorTumorsPatient dataEvidence on Effectiveness of Immune Checkpoint Inhibitors in Patients With Advanced Esophageal Squamous Cell Carcinoma—Reply
Zhao J, Pietrantonio F, Sundar R. Evidence on Effectiveness of Immune Checkpoint Inhibitors in Patients With Advanced Esophageal Squamous Cell Carcinoma—Reply. JAMA Oncology 2023, 9: 1005-1006. PMID: 37166787, DOI: 10.1001/jamaoncol.2023.0975.Commentaries, Editorials and LettersRisk of Squamous Cell Carcinoma of the Breast Following Postmastectomy Implant Reconstruction in Women With Breast Cancer and Carcinoma in Situ
Kinslow C, Yu J, DeStephano D, Kachnic L, Cheng S, Neugut A, Horowitz D. Risk of Squamous Cell Carcinoma of the Breast Following Postmastectomy Implant Reconstruction in Women With Breast Cancer and Carcinoma in Situ. JAMA Surgery 2023, 158: 769-771. PMID: 37074722, PMCID: PMC10116379, DOI: 10.1001/jamasurg.2023.0262.Peer-Reviewed Original ResearchMeSH KeywordsBreastBreast ImplantsBreast NeoplasmsCarcinoma in SituCarcinoma, Squamous CellFemaleHumansMammaplastyMastectomyPTEN Loss Confers Resistance to Anti-PD-1 Therapy in Non-Small Cell Lung Cancer by Increasing Tumor Infiltration of Regulatory T Cells.
Exposito F, Redrado M, Houry M, Hastings K, Molero-Abraham M, Lozano T, Solorzano J, Sanz-Ortega J, Adradas V, Amat R, Redin E, Leon S, Legarra N, Garcia J, Serrano D, Valencia K, Robles-Oteiza C, Foggetti G, Otegui N, Felip E, Lasarte J, Paz-Ares L, Zugazagoitia J, Politi K, Montuenga L, Calvo A. PTEN Loss Confers Resistance to Anti-PD-1 Therapy in Non-Small Cell Lung Cancer by Increasing Tumor Infiltration of Regulatory T Cells. Cancer Research 2023, 83: 2513-2526. PMID: 37311042, DOI: 10.1158/0008-5472.can-22-3023.Peer-Reviewed Original ResearchConceptsNon-small cell lung cancerLung squamous carcinomaAnti-PD-1 therapyRegulatory T cellsCell lung cancerImmunosuppressive microenvironmentLung cancerImmunotherapy resistanceT cellsWorse progression-free survivalCell death protein 1PTEN lossAnti-TGFβ antibodyConversion of CD4PI3K/AKT/mTOR pathwayProgression-free survivalDeath protein 1Treatment of miceImmunosuppressive tumor microenvironmentPTEN/PI3K/AKT/mTOR pathwayAKT/mTOR pathwayPD-L1TLR agonistsTumor rejectionSquamous carcinomaAnal Carcinoma, Version 2.2023, NCCN Clinical Practice Guidelines in Oncology.
Benson A, Venook A, Al-Hawary M, Azad N, Chen Y, Ciombor K, Cohen S, Cooper H, Deming D, Garrido-Laguna I, Grem J, Hecht J, Hoffe S, Hubbard J, Hunt S, Hussan H, Jeck W, Johung K, Joseph N, Kirilcuk N, Krishnamurthi S, Maratt J, Messersmith W, Meyerhardt J, Miller E, Mulcahy M, Nurkin S, Overman M, Parikh A, Patel H, Pedersen K, Saltz L, Schneider C, Shibata D, Skibber J, Sofocleous C, Stotsky-Himelfarb E, Tavakkoli A, Willett C, Williams G, Algieri F, Gurski L, Stehman K. Anal Carcinoma, Version 2.2023, NCCN Clinical Practice Guidelines in Oncology. Journal Of The National Comprehensive Cancer Network 2023, 21: 653-677. PMID: 37308125, DOI: 10.6004/jnccn.2023.0030.Peer-Reviewed Original ResearchConceptsNCCN Clinical Practice GuidelinesAnal carcinomaClinical practice guidelinesPrimary treatmentPractice guidelinesSquamous cell anal carcinomaCommon histologic formExtrapelvic metastatic diseaseMetastatic anal carcinomaSystemic therapy recommendationsAnal canal cancerCurative-intent treatmentAJCC staging systemNCCN guidelinesPerianal cancerMetastatic diseasePersistent diseaseSystemic therapySurgical treatmentMedical oncologyStaging systemOptimal treatmentClinical evaluationHistologic formsTherapy recommendations
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply